Introduction
============

Systemic lupus erythematosus (SLE) is a debilitating systemic autoimmune disease characterized by the production of autoreactive antibodies and multiorgan inflammation \[[@B1]\]. A hallmark of systemic autoimmune diseases is the increased expression of interferon (IFN) type I in both blood and disease-affected tissues \[[@B2]\]. About half of the SLE patients exhibit an IFN type I signature or upregulation of IFN type I-induced genes (IFIGs), which have been found to correlate with disease activity and severity \[[@B3]-[@B5]\].

Another key factor in the pathogenesis of SLE, apart from IFN type I, is interleukin-17A (IL-17A) \[[@B6]-[@B9]\]. IL-17A is produced by several immune cell types, including CD4^+^ T cells (Th17 cells), CD8^+^ T cells, CD4-CD8-CD3^+^ (double-negative, DN) T cells, natural killer cells, γδ-T cells, and mast cells \[[@B10],[@B11]\]. Naïve CD4^+^ T cells differentiate to Th17 cells under the influence of IL-6 and TGF-β \[[@B12]\]. The expansion and stability of the Th17 population is regulated by IL-21 and IL-23, respectively \[[@B13],[@B14]\]. C57BL/6-lpr/lpr mice that lack IL-23 receptor signaling are protected for SLE development \[[@B15]\]. In SLE patients, increased plasma levels of IL-17A correlate with disease activity (SLEDAI) \[[@B6]\]. In addition, in peripheral blood of SLE patients, an increased number of IL-17-producing cells is observed. These cells correlate with disease activity and decrease with treatment \[[@B7],[@B8]\]. IL-17-producing cells have also been found in several affected organs of SLE patients \[[@B7],[@B9]\].

Co-activity between IFN type I and IL-17/Th17 cells has been suggested in autoimmune diseases \[[@B16],[@B17]\]. In experimental autoimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis (MS), IFN type I treatment caused exacerbation if the disease was Th17 driven but was effective if the disease was Th1 driven \[[@B17]\]. In the same study, MS patients that did not respond to IFN type I therapy had higher serum levels of IL-17A before therapy onset \[[@B17]\]. These two observations suggest additional effects of the IFN type I and Th17 system co-acting in the pathogenesis of autoimmune diseases.

Co-activity of IFN type I and Th17 pathways has also been suggested for SLE by the Ro52/TRIM21^-/-^ mouse model. Ro52/TRIM21 is involved in the ubiquitination of interferon regulatory factors (IRFs), a process that limits the IFN type I response \[[@B18]\]. After ear tagging, Ro52/TRIM21^-/-^ mice develop an SLE-like phenotype \[[@B19]\]. Interestingly, when these mice are crossed on an IL-23p19^-/-^ mouse line, they do not develop SLE, indicating that the development of an SLE phenotype through enhanced IFN type I production in these mice is dependent on the IL-17/Th17 pathway.

Yet another important factor involved in the pathogenesis of SLE is B cell-activating factor of the tumor necrosis factor family (*BAFF*). *BAFF* transgenic mice develop lupus-like disease \[[@B20]\], and increased expression of *BAFF* protein has been found in SLE patients, correlating with increased disease activity \[[@B21]-[@B23]\]. We previously described a strong correlation between *BAFF* mRNA expression in monocytes and the IFN type I signature in primary Sjögren syndrome (pSS) patients \[[@B24]\]. Interestingly, IL-21, a cytokine produced by Th17 cells, in combination with *BAFF*, has been reported to induce synergistically the differentiation of human memory B cells into antibody-producing plasma cells in the absence of further co-stimulation \[[@B25]\]. *BAFF* is known to be involved in germinal center formation \[[@B26]\], a process in which IL-17 is also involved \[[@B27]\].

The previously mentioned literature suggests an association between the pathogenic IFN type I and Th17 pathways. So far, no studies have been performed on the co-occurrence of these pathogenic pathways in SLE patients. In this study, we report for the first time a higher percentage of IL-17A and IL-17A/F producing CCR6^+^ T-memory cells in IFN type I-positive SLE patients. Moreover, *BAFF* gene expression in monocytes correlates significantly with IL-21 expression in these CCR6^+^ cells, supporting the concept of co-activity of IFN type I, Th17, and *BAFF* in the pathogenesis of SLE.

Methods
=======

Patients
--------

The 25 patients fulfilling the American College of Rheumatology revised criteria for SLE \[[@B28]\] were recruited at the outpatient clinic of the Immunology Department and the Rheumatology Department of the Erasmus Medical Center Rotterdam. The level of disease activity was assessed by using the SLEDAI \[[@B29]\]. Fifteen healthy controls (HCs), neither with autoimmune diseases nor using corticosteroids, were included. Characteristics of patients and controls are summarized in Table [1](#T1){ref-type="table"}. The Medical Ethical Review Committee of the Erasmus MC approved the study, and written informed consent was obtained.

###### 

Demographics and clinical characteristics of participants

  **Variable**                          **SLE patients**   **Healthy controls**  
  ------------------------------------ ------------------ ---------------------- --------------
  Demographics                                                                          
     Number of females, *n* (%)            9/9 (100%)          14/16 (88%)        15/15 (100%)
     Age (years)                          41.3 ± 17.5          39.8 ± 15.7        41.0 ± 14.0
     Race, *n* (%)                                                                      
     Caucasian                             8/9 (89%)            7/16 (44%)        15/15 (100%)
     Black                                  0/9 (0)             8/16 (50%)          0/15 (0)
     Asian                                  0/9 (0)              0/16 (0)           0/15 (0)
     Mixed race                            1/9 (11%)            1/16 (6%)           0/15 (0)
  Clinical                                                                              
     Disease duration (years)              12.1 ± 8.0          14.4 ± 11.3             \-
     Mucocutaneous, *n* (%)                3/9 (33%)           10/16 (63%)             \-
     Arthritis, *n* (%)                    7/9 (78%)            6/16 (38%)             \-
     Serositis, *n* (%)                    1/9 (11%)            3/16 (19%)             \-
     Nephritis, *n* (%)                    3/9 (33%)            9/16 (56%)             \-
     Neuropsychiatric, *n* (%)             1/9 (11%)            3/16 (19%)             \-
     Hematologic, n (%)                    6/9 (67%)           12/16 (75%)             \-
  Laboratory                                                                            
     ANA positivity, *n* (%)               9/9 (100%)          16/16 (100%)            \-
     Anti-ds-DNA positivity, *n* (%)       5/9 (56%)           10/16 (63%)             \-
  Treatment                                                                             
     Hydroxychloroquine, *n* (%)           7/9 (78%)           11/16 (69%)             \-
     Corticosteroids, *n* (%)              5/9 (56%)           10/16 (63%)             \-
     Mycophenolate mofetil, *n* (%)         0/9 (0)             4/16 (25%)             \-
     Azathioprine, *n* (%)                 2/9 (22%)            3/16 (19%)             \-
     Cyclophosphamide, *n* (%)              0/9 (0)             1/16 (6%)              \-

Values are the mean ± SD, median (25% quartile,75% quartile) or number (%) of patients, depending on whether the data are continuous or dichotomous, and whether the data are normally distributed or not.

Blood collection and isolation of monocytes
-------------------------------------------

Blood was collected in clotting tubes for serum preparation (stored at -80°C) and in sodium-heparin tubes for peripheral blood mononuclear cell (PBMC) preparation, as described previously \[[@B30]\]. CD14-positive monocytes were isolated as described \[[@B30]\].

RQ-PCR
------

Total RNA was isolated from purified monocytes followed by cDNA preparation and real-time quantitative polymerase chain reaction (RQ-PCR) analysis by using predesigned primer/probe sets (Applied Biosystems) \[[@B30]\]. For calculation of relative expression, all samples were normalized against expression of the household gene Abl \[[@B31]\]. Fold-change values were determined from normalized CT values by using the 2^-ΔΔCT^ method (User Bulletin; Applied Biosystems, Foster City, CA, USA).

Flow cytometry
--------------

PBMCs were restimulated, stained, and measured with flow cytometry, as previously described \[[@B32]\]. For extracellular staining, CD4, CD45RO, and CCR6 monoclonal antibodies were obtained from BD Biosciences (San Diego, CA, USA), and CD25 antibodies from Biolegend Inc. (San Diego, CA, USA). For intracellular staining, IL-17A, IL-17F, IL-21, and IL-22 monoclonal antibodies were obtained from eBioscience, and IL-17A monoclonal antibodies from Biolegend Inc. Samples were measured on a FACScantoII flow cytometer (BD Biosciences). Analysis was performed by using FlowJo v7.6 research software (Tree Star Inc. Ashland, OR, USA).

Factor analysis
---------------

The expression levels of 11 IFN type I-inducible genes (previously found to be increased in SLE) were submitted to a principal component analysis to identify correlated groups of genes to reduce data complexity. Kaiser-Meyer-Olkin measure of sampling adequacy was 0.839 with a significant Bartlett test of sphericity (*P* \< 0.001). Eigenvalues were derived to assess the amount of variance explained by each component factor.

Statistical analyses
--------------------

Statistical analyses were performed by using the SPSS 20.0 package. When data were not normally distributed, values were expressed as medians with interquartile ranges (IQRs), and comparisons were made by using the nonparametric Mann--Whitney *U* test. In case of more than two samples, the nonparametric Kruskal-Wallis test was performed. Correlations were assessed by using either the Pearson correlation test for normally distributed data or Spearman rho when data were not normally distributed. Differences were considered statistically significant if *P* \< 0.05.

Results
=======

Prevalence of the IFN type I signature in SLE patients
------------------------------------------------------

In monocytes of 25 SLE patients and 15 HCs, we assessed the expression levels of 11 IFIGs previously assessed in monocytes from patients with primary Sjögren syndrome (pSS) (IFI27, IFI44L, IFIT3, IFITM1, SERPING1, IFIT1, IFIT2, LY6E, IFI44, XAF1, and MXA) \[[@B24]\], and the expression of which was also found to be increased in SLE patients \[[@B2],[@B3],[@B33],[@B34]\]. To reduce data complexity, expression levels of the 11 genes were submitted to a principal component analysis to identify correlated groups of genes. The results of the principal component analysis identified a subset of four genes (*IFI44L, IFITM1, SERPING1*, and *LY6E*) to explain 95% of the total variance of the 11 IFN type I-inducible genes within the SLE cohort. Given that the expression of these four IFN type I-inducible genes was not normally distributed, log transformations of expression values were performed, and IFN scores were calculated as described for pSS \[[@B24]\]. MeanHC and SD~HC~ of each gene in the HC-group were used to standardize expression levels. IFN scores per subject represent the sum of these standardized scores. When we set the threshold for a positive IFN type I signature at IFN score of 8 \[[@B24]\], 64% of SLE patients displayed an IFN type I signature, and one of the 15 HC subjects (7%) (Figure [1](#F1){ref-type="fig"}A,B).

![**Prevalence of IFN type I signature in SLE patients. (A)** Heatmap showing gene expression of four IFN type I-inducible genes in monocytes of SLE patients (*n* = 25) and HCs (*n* = 15). On the left, the HCs are depicted, and on the right, the SLE patients are depicted and subdivided into IFN type I signature-positive and -negative patients. Red indicates high gene expression, and cases are depicted according to IFN scores. **(B)** Distribution of IFN scores in IFN type I signature-positive and -negative patients and HCs. In red, IFN type I-positive cases are depicted. Blue lines represent medians. *P* values are shown, and to compare medians, the Mann--Whitney *U* test was used.](ar4499-1){#F1}

SLE patients with IFN type I signature show higher percentages of IL-17A, IL-17F, and IL-21 producing CCR6^+^ cells
-------------------------------------------------------------------------------------------------------------------

Because CCR6 enriches for Th17 cells \[[@B35]-[@B37]\], CCR6^+^ cells were selected after gating on lymphocytes and memory Th cells (CD4^+^CD45RO^+^ cells) within PBMCs and after CD25+ cells were excluded. To investigate whether the IFN type I signature is associated with an increase in Th17 cytokines expressed by memory CCR6^+^ T cells, we measured the percentages of IL-17A, IL-17F, IL-22 and IL-21 producing CCR6^+^ T memory cells in SLE patients positive for the IFN type I signature (IFN^+^) and patients negative for the signature (IFN^-^) and HC. The percentages of CCR6^+^ cells within the CD4^+^CD45RO^+^ T-cell population and within total lymphocytes were comparable between the three studied groups (data not shown). Interestingly, the percentages of CCR6^+^IL^-^17A^+^ cells were significantly increased in IFN^+^ patients, as compared with IFN^-^ patients (*P* = 0.03), and a higher trend was observed compared with HCs (*P* = 0.07) (Figure [2](#F2){ref-type="fig"}A). The percentages of CCR6^+^IL^-^17F^+^ and, in particular, the IL-17A/IL-17F double producers were significantly increased in the IFN^+^ group compared with HC (*P* = 0.009) (Figure [2](#F2){ref-type="fig"}B, and see Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). The percentages of CCR6^+^IL^-2^2^+^ cells showed a higher trend for IFN^+^ versus IFN^-^ patients (^P^ = 0.06) and IFN^+^ patients versus HC (*P* = 0.09) (Figure [2](#F2){ref-type="fig"}C). The percentages of IL-21 expressing CCR6^+^ cells were also significantly increased in IFN^+^ patients compared with IFN^-^ patients (Figure [2](#F2){ref-type="fig"}D). These data suggest an association between the presence of the IFN type I signature and the expression of Th17 cytokines in SLE.

![**SLE patients with IFN type I signature show higher percentages of IL-17A and IL-17A/IL-17 F producing CCR6**^**+**^**cells. (A-D)**. Proportions of IL-17A **(A)**, IL-17 F **(B)**, IL-22 **(C)**, and IL-21 **(D)** expressing cells within CCR6^+^ memory T-cell population in PBMCs of IFN^-^ (*n* = 9) and IFN^+^ (*n* = 16) patients and HC (*n* = 15). All proportions were measured by intracellular flow cytometry. Horizontal line indicates median. \**P* \< 0,05; \*\**P* \< 0,01; to compare means, a Kruskal-Wallis test was used followed by Mann--Whitney *U* test.](ar4499-2){#F2}

In addition, we investigated whether the Th17 cytokine production is associated with disease activity as assessed by SLEDAI scores. No significant correlations were observed between the SLEDAI scores and IL-17A and/or IL-17F expression (data not shown). Except for race, no differences in demographic, clinical, or laboratory data were found between IFN^+^, IFN^-^ SLE patients and/or HCs (Table [1](#T1){ref-type="table"}).

*BAFF* mRNA expression is correlated with IL-21 expression within CCR6^+^ memory T cells
----------------------------------------------------------------------------------------

Correlating the expression of IFIGs (as reflected by the total IFN score) with other parameters assessed in this study, we observed a significant positive correlation between the expression of IL-17A and IL-17F within CCR6^+^ cells and IFIG expression (Figure [3](#F3){ref-type="fig"}A,B). Also in this SLE cohort, IFIG expression correlated strongly with the *BAFF* mRNA expression in monocytes (*r* = 0.527; *P* \< 0.0001) (Figure [3](#F3){ref-type="fig"}C). No correlation was observed between *BAFF* and IL-17A and/or IL-17F expression. However, we did find a significant correlation between *BAFF* mRNA and the percentages of IL-21 producing CCR6^+^ cells (*r* = 0.406; *P* = 0.010) (Figure [3](#F3){ref-type="fig"}D). Both *BAFF* and IL-21 are involved in the selection and activation of B cells, which is crucial in the pathogenesis of SLE, indicating that downstream factors of the IFN type I and Th17 pathways might also be associated.

![***BAFF*mRNA expression is correlated with IL-21 expression within CCR6**^**+**^**memory T cells. (A)** Correlation between IFN score and IL-17A expression within CCR6^+^ memory T cells in SLE patients (*n* = 25). **(B)** Correlation between IFN score and IL-17 F expression within CCR6^+^ memory T cells in SLE patients (*n* = 25). **(C)** Correlation between monocyte *BAFF* mRNA expression and IFN score in SLE patients and HCs (*n* = 40). **(D)** Correlation between monocyte *BAFF* mRNA expression and IL-21 expression within CCR6^+^ cells in SLE patients and HCs (*n* = 40). The correlation coefficients (*r*) and *P* values are shown. For correlations, the Spearman rho correlation test was used in **(A)**, **(B)**, and **(D)**, and the Pearson correlation test was used in **(C)**.](ar4499-3){#F3}

Discussion
==========

Here we show for the first time a co-occurrence of increased IFN type I activity and increased IL-17/Th17 system in SLE patients. We found increased percentages of IL-17A, IL-17A/IL-17F, and IL-21 producing CCR6^+^ T memory cells in IFN type I-positive SLE patients. This finding further strengthens the hypothesis that IFN type I and Th17 cells, by co-acting, contribute to the pathogenesis of SLE. Further research to understand the link between these two pathways is warranted.

A possible mechanism explaining the co-occurrence of IFN type I and IL-17/Th17 immune pathway in SLE could be that both IFN type I and production of IL-6 and IL-23 by DCs are regulated through IRF-5 \[[@B38],[@B39]\]. Activation of TLR signaling on DCs will then lead to simultaneous enhancement of both pathways. Evidence suggests that TLR7 activation of plasmacytoid DCs, the main producers of IFN type I, promotes and modifies Th17 cell differentiation and function \[[@B40]\]. IFN type I itself is also able to promote Th17 differentiation and IL-17 production through induction of STAT-3 in T cells and IL-6 in DCs \[[@B41],[@B42]\]. In addition, IFN type I-conditioned monocytes differentiate into DCs, driving the development of Th17 cells from autologous naive CD4^+^ T cells \[[@B43]\].

In addition to the direct effect of IFN type I on Th17 cells, IFN type I may also act indirectly through the production of *BAFF*. *BAFF* is reported to be involved in DC maturation and DC-driven Th17 cell differentiation *in vitro*\[[@B44]\]. *BAFF* gene silencing ameliorated joint pathology and inhibited the generation of Th17 cells in the joints of a collagen-induced arthritis (CIA) mouse model \[[@B44]\]. In turn, IL-17A can induce the formation of neutrophil extracellular traps (NETs) \[[@B45]\], which could potentially provide new autoantigens to active TLRs on DCs, thereby forming a proinflammatory loop.

We find a correlation between *BAFF*, an IFN type I inducible factor, and the Th17 produced cytokine IL-21. Ettinger *et al.*\[[@B25]\] showed that IL-21 together with *BAFF* promotes B-cell responses by bypassing the need for T-cell help or TLR signaling. As these downstream factors are both involved in activation and selection of B cells, these findings again support the concept that IFN type I and the Th17 pathway act together in driving the disease process of SLE.

IL-21 is also produced by T follicular helper (Tfh) cells, and production by Tfh is crucial for B-cell immunity. By gating for CCR6 expression, we exclude the Tfh cells from our analysis. We therefore measured the production of IL-21 by total memory T cells (CD4^+^CD45RO^+^), which include the Tfh cells. The expression of IL-21 by these cells is significantly increased in IFN^+^ patients compared with IFN^-^ patients and HCs, and IL-21 expression by memory cells also strongly correlated with IFN score (data not shown). These data suggest that Tfh effector function may also be increased in IFN^+^ patients; however, further studies are required.

By gating on CCR6^+^ cells, we may miss certain IL-17A-producing cells, including Tfh cells. However, the percentages of IL-17A, IL-17F, and IL-22-producing cells within the CCR6^-^ population were 10-- to 20-fold lower than in the CCR6^+^ population, as described previously by Acosta-Rodriguez *et al.*\[[@B35]\]. In addition, we did not find a difference in cytokine production between the groups when gating on total CD4^+^CD45RO^+^ memory T cells, possibly because the percentages are very small.

In contrast to others, we did not find a correlation between SLEDAI and Th17 cytokines \[[@B6]\]. This might be due to the relatively low patient number, which is a limitation of our study.

In addition to flow-cytometry analysis of cytokine expression by PBMCs, we also measured cytokine levels in the serum of the participants in this study (data not shown). Unfortunately, we were unable to detect IL-17A and F in most of the samples. We did find IL-22 in serum samples of all subjects, but they were not different between the groups. We also found higher levels of IL-21 in IFN^+^ patients compared with IFN^-^ patients and HCs, but we could detect IL-21 in only one third of the samples.

Although we do not show a functional link between IFN type I and the Th17 pathway, our findings provide the first support for co-occurrence of increased IFN type I activity and increased IL-17/Th17 system in SLE. The Th17-IFN type I interaction found in this study might have implications for future treatment of SLE and other systemic autoimmune diseases in which IFN type I plays a role. Preliminary results from a phase IIa trial with human IgG1κ anti-IFNα antibody, in 87 SLE patients, showed so far a 40% reduction in IFN type I-induced gene expression but no clinical effect compared with placebo (abstract; Merrill J *et al.*^*a*^). Our data indicate that IFN type I might act in concert with Th17 cytokines, paving the way for combination therapies, possibly resulting in more significant clinical effects in the future.

Conclusion
==========

The aim of this study was to investigate whether CCR6^+^ memory T-helper cells and their cytokine expression was increased in SLE patients. In addition, we examined whether this increase is related to the presence of IFN type I signature. In the present study, we showed that IFN^+^ patients had an increased percentage of IL-17A and IL-17A/IL-17F double-producing CCR6^+^ memory T helper cells in the blood compared to IFN negative patients and HCs. Interestingly, the IL-17A and IL-17F expression within the CCR6^+^ cells correlated significantly with IFIG expression. Moreover, monocyte *BAFF* expression in these patients correlated significantly with IL-21 producing CCR6^+^ memory T-helper cells.

Thus, this study adds new insight into the co-occurrence of the two pathogenic pathways in SLE, the IFN type I and the Th17 pathway, and showed for the first time a higher percentage of IL-17A and IL-17A/IL-17F double-producing CCR6^+^ memory T-helper cells in IFN^+^ SLE patients. These findings indicate that IFN type I co-acts with Th17 cytokines in SLE pathogenesis, and further functional studies, including understanding the mechanism, are warranted.

Endnote
=======

^a^J. Merrill, V. Chindalore, J. Box, N. Rothfield, J. Fiechtner, J. Sun, D. Ethgen. Results of a randomized placebo-controlled, phase 2a study of sifalimumab, an anti-interferon-alpha monoclonal antibody, administered subcutaneously in subjects with systemic lupus erythematosus \[abstract\]. \[2011\] \[THU0411\].
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###### Additional file 1: Figure S1

\(A\) Representative graphs of proportions of IL-17A- and IL-17F-expressing cells within CCR6^+^ memory T-cell population (defined as CD4^+^CD45RO^+^CD25-CCR6^+^) in PBMCs of IFN negative (IFN^-^) and IFN positive (IFN^+^) patients and healthy controls (HCs). (B) Representative graphs of proportions of IL-17A and IL-22-expressing cells within CCR6^+^ memory T-cell population in PBMCs of IFN^-^ and IFN^+^ patients and HCs. (C) Representative graphs of proportions of IL-21-expressing cells within CCR6^+^ memory T-cell population in PBMCs of IFN- and IFN^+^ patients and HCs.
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